SANTA CRUZ BIOTECHNOLOGY, INC.

CDKL5 (m): 293T Lysate: sc-178387

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

Cell cycle progression is controlled in part by a family of cyclin proteins and cyclin-dependent kinases (Cdks). Cdk proteins work in concert with the cyclins to phosphorylate key substrates involved in each phase of cell cycle progression. Another family of proteins, Cdk inhibitors, also plays a role in regulating the cell cycle by binding to cyclin-Cdk complexes and modulating their activity. CDKL5 (cyclin-dependent kinase-like 5) is a 1,030 amino acid protein that belongs to the CMGC Ser/Thr protein kinase family. Expressed in brain, lung, kidney, prostate, ovary, placenta, pancreas and testis, CDKL5 is thought to play a role in cell cycle regulation. Defects in CDKL5 are a cause of several disorders, such as X-linked infantile spasm syndrome and Rett syndrome.

REFERENCES

1. Tao, J., Van Esch, H., Hagedorn-Greiwe, M., Hoffmann, K., Moser, B., Raynaud, M., Sperner, J., Fryns, J.P., Schwinger, E., Gécz, J., Ropers, H.H. and Kalscheuer, V.M.2004. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am. J. Hum. Genet. 75: 1149-1154.
2. Buoni, S., Zannolli, R., Colamaria, V., Macucci, F., di Bartolo, R.M., Corbini, L., Orsi, A., Zappella, M. and Hayek, J. 2006. Myoclonic encephalopathy in the CDKL5 gene mutation. Clin. Neurophysiol. 117: 223-227.
3. Nectoux, J., Heron, D., Tallot, M., Chelly, J. and Bienvenu, T. 2006. Maternal origin of a novel C-terminal truncation mutation in CDKL5 causing a severe atypical form of Rett syndrome. Clin. Genet. 70: 29-33.
4. Bertani, I., Rusconi, L., Bolognese, F., Forlani, G., Conca, B., De Monte, L., Badaracco, G., Landsberger, N. and Kilstrup-Nielsen, C. 2006. Functional consequences of mutations in CDKL5, an X-linked gene involved in infantile spasms and mental retardation. J. Biol. Chem. 281: 32048-32056.
5. Archer, H.L., Evans, J., Edwards, S., Colley, J., Newbury-Ecob, R., O'Callaghan, F., Huyton, M., O'Regan, M., Tolmie, J., Sampson, J., Clarke, A. and Osborne, J. 2006. CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J. Med. Genet. 43: 729-734.
6. Van Esch, H., Jansen, A., Bauters, M., Froyen, G. and Fryns, J.P. 2007. Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes. Am. J. Med. Genet. A 143A: 364-369.
7. Grosso, S., Brogna, A., Bazzotti, S., Renieri, A., Morgese, G. and Balestri, P. 2007. Seizures and electroencephalographic findings in CDKL5 mutations: case report and review. Brain Dev. 29: 239-242.
8. Bahi-Buisson, N., Kaminska, A., Boddaert, N., Rio, M., Afenjar, A., Gérard, M., Giuliano, F., Motte, J., Héron, D., Morel, M.A., Plouin, P., Richelme, C., des Portes, V., Dulac, O., Philippe, C., Chiron, C., Nabbout, R. and Bienvenu, T. 2008. The three stages of epilepsy in patients with CDKL5 mutations. Epilepsia 49: 1027-1037.

CHROMOSOMAL LOCATION

Genetic locus: Cdkl5 (mouse) mapping to X F4.

PRODUCT

CDKL5 (m): 293T Lysate represents a lysate of mouse CDKL5 transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

CDKL5 (m): 293T Lysate is suitable as a Western Blotting positive control for mouse reactive CDKL5 antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.